Lantheus Holdings 2025 Q1 Earnings Misses Targets as Net Income Drops 44%
Thursday, May 8, 2025 6:10 am ET
54min read LNTH Trend
Revenue
Lantheus Holdings saw a slight increase of 0.8% in total revenue, reaching $372.76 million in Q1 2025 compared to $369.98 million in the same quarter of the previous year. PYLARIFY was the largest contributor to revenue, generating $257.65 million. DEFINITY followed with $79.21 million, while TechneLite added $19.71 million. Other precision diagnostics brought in $5.44 million, and strategic partnerships and other revenue totaled $10.75 million, culminating in total revenues of $372.76 million.
Earnings/Net Income
Lantheus Holdings experienced a significant decline in earnings per share, which fell 44.5% to $1.06 in Q1 2025 from $1.91 in Q1 2024. Similarly, net income decreased by 44.3% to $72.94 million in Q1 2025, down from $131.07 million in the previous year. This performance indicates a challenging quarter for the company.
Price Action
The stock price of Lantheus Holdings has tumbled 10.47% during the latest trading day, has plummeted 22.86% during the most recent full trading week, and has tumbled 11.47% month-to-date.
Post-Earnings Price Action Review
The strategy of acquiring Lantheus Holdings shares post-revenue increase and holding them for 30 days yielded a modest 5.22% return, underperforming against the benchmark with an excess return of -78.86%. The approach had a compound annual growth rate (CAGR) of 1.03%, reflecting a maximum drawdown of -17.75% and volatility at 12.17%. While this strategy managed risks effectively, it failed to leverage broader market gains, reflecting a need for reevaluation in the context of Lantheus' current market dynamics and strategic transitions. The company's stock performance indicates a need for strategic adjustments to align with market expectations and capitalize on potential growth opportunities.
CEO Commentary
"We are laying the foundation for the next chapter of Lantheus’ business with the acquisition of Evergreen Theragnostics and planned acquisition of Life Molecular Imaging, both of which add growth drivers that complement our business and diversify our revenues. These transactions also add exciting new pipeline programs in both late- and early-stage development and key capabilities that enable Lantheus to progress novel programs from bench to clinic," said Brian Markison, Chief Executive Officer at Lantheus. "With robust cash flow and a disciplined capital allocation strategy, we are advancing our position as the leading radiopharmaceutical-focused company."
Guidance
Lantheus provided updated interim corporate guidance for full-year 2025 revenue and adjusted fully diluted earnings per share. The Company expects continued growth, driven by strategic acquisitions and new product developments. Additionally, they plan to file a New Drug Application (NDA) for MK-6240 in the third quarter of 2025, reflecting optimism in their expanding pipeline and market positioning.
Additional News
Lantheus Holdings has been active in reshaping its strategic direction, highlighted by the acquisition of Evergreen Theragnostics and the pending acquisition of Life Molecular Imaging. These moves aim to enhance Lantheus' capabilities in radiopharmaceuticals, focusing on advanced PET imaging and therapeutic solutions. The company also announced the divestiture of its SPECT business to SHINE Technologies, allowing Lantheus to concentrate on innovative diagnostics and therapeutics. These strategic decisions underscore Lantheus' commitment to advancing its portfolio and maintaining leadership in the radiopharmaceutical sector, aiming for long-term growth and enhanced shareholder value.
Ask Aime: What's the future of Lantheus Holdings (LNTH), and how should I trade?
